Published in Int Urol Nephrol on January 01, 1997
The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer (2006) 2.70
The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology (2000) 2.36
hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer (2005) 2.21
The essential toxin: impact of zinc on human health. Int J Environ Res Public Health (2010) 2.09
Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate (1999) 2.03
Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion (2005) 1.74
Zinc and zinc transporters in normal prostate and the pathogenesis of prostate cancer. Front Biosci (2005) 1.50
Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate (2002) 1.46
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis (2012) 1.42
Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis (2004) 1.37
Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland. Adv Nutr (2011) 1.35
Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell Int (2006) 1.26
Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res (2008) 1.12
Zinc is decreased in prostate cancer: an established relationship of prostate cancer! J Biol Inorg Chem (2010) 1.11
Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol (2013) 1.11
Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol (2011) 1.03
Ras responsive element binding protein-1 (RREB-1) down-regulates hZIP1 expression in prostate cancer cells. Prostate (2010) 1.00
Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res (2009) 0.99
Zinc intake from supplements and diet and prostate cancer. Nutr Cancer (2009) 0.97
Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr (2011) 0.94
Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity. J Cell Biochem (2009) 0.92
Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients (2012) 0.91
Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway. Prostate (2008) 0.91
Risk stratification of prostate cancer patients based on EPS-urine zinc content. Am J Cancer Res (2014) 0.89
Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach. Chemotherapy (Los Angel) (2015) 0.88
hZIP1 zinc transporter down-regulation in prostate cancer involves the overexpression of ras responsive element binding protein-1 (RREB-1). Prostate (2011) 0.86
Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. Int J Cancer (2012) 0.85
Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis (2011) 0.84
Age-related histological and zinc content changes in adult nonhyperplastic prostate glands. Age (Dordr) (2013) 0.82
Metal selectivity by the virulence-associated yersiniabactin metallophore system. Metallomics (2015) 0.82
Resveratrol-zinc combination for prostate cancer management. Cell Cycle (2014) 0.81
Expression of the ZNT (SLC30) family members in the epithelium of the mouse prostate during sexual maturation. J Mol Histol (2008) 0.81
A Critical Assessment of Epidemiology Studies Regarding Dietary/Supplemental Zinc and Prostate Cancer Risk. Open Urol Nephrol J (2008) 0.80
Gene-environment interactions between JAZF1 and occupational and household lead exposure in prostate cancer among African American men. Cancer Causes Control (2014) 0.80
Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer. Indian J Clin Biochem (2015) 0.78
Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate. Proc Natl Acad Sci U S A (2016) 0.78
PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis. Cell Death Dis (2013) 0.78
Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells. J Nutr Biochem (2009) 0.77
High-dose dietary zinc promotes prostate intraepithelial neoplasia in a murine tumor induction model. Asian J Androl (2009) 0.77
Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas. Expert Opin Ther Targets (2016) 0.76
Analysis of Zinc-Exporters Expression in Prostate Cancer. Sci Rep (2016) 0.75
Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.75
Zinc transporters and dysregulated channels in cancers. Front Biosci (Landmark Ed) (2017) 0.75
Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity. Am J Cancer Res (2015) 0.75
Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget (2016) 0.75
Response to commentary "Zinc is decreased in prostate cancer: an established relationship of prostate cancer!". J Biol Inorg Chem (2010) 0.75
The Effect of Zinc and Selenium Supplementation Mode on Their Bioavailability in the Rat Prostate. Should Administration Be Joint or Separate? Nutrients (2016) 0.75
Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc. Mol Pharmacol (2016) 0.75
Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer. Int Urol Nephrol (1996) 1.13
[The Study of Psychological Characteristics of Children and Adolescents with Digestive Diseases]. Vestn Ross Akad Med Nauk (2015) 0.75
[Roentgenotopometry in the radiation therapy of prostate cancer]. Med Radiol (Mosk) (1981) 0.75
[Lymphography in cancer of the prostate]. Med Radiol (Mosk) (1985) 0.75
[Disordered plasma coagulation and thrombocyte function in prostate cancer and the principles of their correction]. Urol Nefrol (Mosk) (1979) 0.75
[Changes in nephron structure in experimental nephrocalcinosis]. Urol Nefrol (Mosk) (1970) 0.75
[The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action]. Urol Nefrol (Mosk) (1996) 0.75
[The late results of the combined hormonal chemoradiation treatment of prostatic cancer]. Urol Nefrol (Mosk) (1996) 0.75
[A case of infiltrative lipoma of retroperitoneal space]. Vestn Rentgenol Radiol (1995) 0.75
[Results of gamma teletherapy of prostate cancer patients]. Med Radiol (Mosk) (1983) 0.75
[A clinical case of IgA deficiency]. Sov Med (1990) 0.75
[Effect of the hormonal treatment of prostate cancer on the hemostasis system]. Urol Nefrol (Mosk) (1981) 0.75
[Changes in the physico-chemical properties of erythrocytes in various neoplastic diseases]. Patol Fiziol Eksp Ter (1984) 0.75
[Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer]. Urologiia (2001) 0.75
[Complex treatment of prostate cancer patients]. Urol Nefrol (Mosk) (1984) 0.75
[The role of lymphography in the choice and planning of treatment in patients with malignant tumors of the lesser pelvis]. Vopr Onkol (1987) 0.75
[Histological structure of the prostate and its zinc content at various ages]. Arkh Anat Gistol Embriol (1981) 0.75
[Transrectal longitudinal scanning in the diagnosis of diseases of the prostate gland]. Urol Nefrol (Mosk) (1987) 0.75